Stefania Ferrari

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7731276/stefania-ferrari-publications-by-year.pdf
Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

61 papers	1,365 citations	19 h-index	35 g-index
67 ext. papers	1,598 ext. citations	6.8 avg, IF	3.77 L-index

#	Paper	IF	Citations
61	Intrinsic Fluorometric Reporters of Pteridine Reductase 1, a Target for Antiparasitic Agents. *Physchem*, **2022**, 2, 131-144		
60	Intrinsic Fluorescence of the Active and the Inactive Functional Forms of Human Thymidylate Synthase. *ChemBioChem*, **2021**, 22, 1800-1810	3.8	1
59	Folic Acid-Peptide Conjugates Combine Selective Cancer Cell Internalization with Thymidylate Synthase Dimer Interface Targeting. *Journal of Medicinal Chemistry*, **2021**, 64, 3204-3221	8.3	4
58	A Peptidic Thymidylate-Synthase Inhibitor Loaded on Pegylated Liposomes Enhances the Antitumour Effect of Chemotherapy Drugs in Human Ovarian Cancer Cells. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	3
57	Identification of a 2,4-diaminopyrimidine scaffold targeting Trypanosoma brucei pteridine reductase 1 from the LIBRA compound library screening campaign. *European Journal of Medicinal Chemistry*, **2020**, 189, 112047	6.8	3
56	Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics. *European Journal of Medicinal Chemistry*, **2019**, 183, 111676	6.8	10
55	SAR Studies and Biological Characterization of a Chromen-4-one Derivative as an Anti- Agent. *ACS Medicinal Chemistry Letters*, **2019**, 10, 528-533	4.3	3
54	Structural Comparison of and Human Thymidylate Synthase Complexes with the Substrate dUMP and Its Analogue FdUMP Provides Hints about Enzyme Conformational Variabilities. *Molecules*, **2019**, 24,	4.8	11
53	Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections. *Journal of Medicinal Chemistry*, **2019**, 62, 3989-4012	8.3	11
52	Structural and Functional Characterization of the Human Thymidylate Synthase (hTS) Interface Variant R175C, New Perspectives for the Development of hTS Inhibitors. *Molecules*, **2019**, 24,	4.8	1
51	Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform. *SLAS Discovery*, **2019**, 24, 346-361	3.4	9
50	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. *European Journal of Medicinal Chemistry*, **2018**, 146, 423-434	6.8	19
49	Proteomic and Bioinformatic Studies for the Characterization of Response to Pemetrexed in Platinum Drug Resistant Ovarian Cancer. *Frontiers in Pharmacology*, **2018**, 9, 454	5.6	6
48	Conformational Propensity and Biological Studies of Proline Mutated LR Peptides Inhibiting Human Thymidylate Synthase and Ovarian Cancer Cell Growth. *Journal of Medicinal Chemistry*, **2018**, 61, 7374-7380	8.3	5
47	Human Thymidylate Synthase Inhibitors Halting Ovarian Cancer Growth. *Vitamins and Hormones*, **2018**, 107, 473-513	2.5	9
46	Scaffolds and Biological Targets Avenue to Fight Against Drug Resistance in Leishmaniasis. *Annual Reports in Medicinal Chemistry*, **2018**, 51, 39-95	1.6	4
45	Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds. *European Journal of Medicinal Chemistry*, **2017**, 126, 1129-1135	6.8	17

44	Exploiting the 2-Amino-1,3,4-thiadiazole Scaffold To Inhibit Pteridine Reductase in Support of Early-Stage Drug Discovery. *ACS Omega*, **2017**, 2, 5666-5683	3.9	17
43	Target-based approaches for the discovery of new antimycobacterial drugs. *Drug Discovery Today*, **2017**, 22, 576-584	8.8	18
42	Chroman-4-One Derivatives Targeting Pteridine Reductase 1 and Showing Anti-Parasitic Activity. *Molecules*, **2017**, 22,	4.8	25
41	X-ray crystal structures of Enterococcus faecalis thymidylate synthase with folate binding site inhibitors. *European Journal of Medicinal Chemistry*, **2016**, 123, 649-664	6.8	9
40	Comparing Drug Images and Repurposing Drugs with BioGPS and FLAPdock: The Thymidylate Synthase Case. *ChemMedChem*, **2016**, 11, 1653-66	3.7	12
39	Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs. *Journal of Medicinal Chemistry*, **2016**, 59, 7598-616	8.3	30
38	Virtual Screening and X-ray Crystallography Identify Non-Substrate Analog Inhibitors of Flavin-Dependent Thymidylate Synthase. *Journal of Medicinal Chemistry*, **2016**, 59, 9269-9275	8.3	16
37	Hotspots in an obligate homodimeric anticancer target. Structural and functional effects of interfacial mutations in human thymidylate synthase. *Journal of Medicinal Chemistry*, **2015**, 58, 3572-81	8.3	18
36	Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance. *Drug Resistance Updates*, **2015**, 23, 20-54	23.2	38
35	2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1. *ACS Chemical Biology*, **2015**, 10, 705-14	4.9	95
34	The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment. *Journal of Medicinal Chemistry*, **2015**, 58, 4857-73	8.3	109
33	Current and Future Chemotherapy for Chagas Disease. *Current Medicinal Chemistry*, **2015**, 22, 4293-312	4.3	37
32	2-[N-Alkyl(R-phenyl)-aminomethyl]-3-phenyl-7-trifluoromethylquinoxalines as anticancer agents inhibitors of folate enzymes. *European Journal of Medicinal Chemistry*, **2014**, 75, 169-83	6.8	7
31	Internalization and stability of a thymidylate synthase Peptide inhibitor in ovarian cancer cells. *Journal of Medicinal Chemistry*, **2014**, 57, 10551-6	8.3	9
30	Optimization of peptides that target human thymidylate synthase to inhibit ovarian cancer cell growth. *Journal of Medicinal Chemistry*, **2014**, 57, 1355-67	8.3	17
29	Ligand-based discovery of N-(1,3-dioxo-1H,3H-benzo[de]isochromen-5-yl)-carboxamide and sulfonamide derivatives as thymidylate synthase A inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 663-8	2.9	8
28	2′Deoxyuridine 5′monophosphate substrate displacement in thymidylate synthase through 6-hydroxy-2H-naphtho[1,8-bc]furan-2-one derivatives. *Journal of Medicinal Chemistry*, **2013**, 56, 9356-60	8.3	6
27	Biochemical effects of riluzole on Leishmania parasites. *Experimental Parasitology*, **2013**, 133, 250-4	2.1	6

26	Targeting the Trypanosomatidic Enzymes Pteridine Reductase and Dihydrofolate Reductase **2013**, 445-472		2
25	Modulation of the expression of folate cycle enzymes and polyamine metabolism by berberine in cisplatin-sensitive and -resistant human ovarian cancer cells. *International Journal of Oncology*, **2013**, 43, 1269-80	4.4	36
24	Protein–Protein Interaction Inhibitors: Case Studies on Small Molecules and Natural Compounds **2013**, 31-60		5
23	Inhibitor of ovarian cancer cells growth by virtual screening: a new thiazole derivative targeting human thymidylate synthase. *Journal of Medicinal Chemistry*, **2012**, 55, 10272-6	8.3	18
22	The structure of Enterococcus faecalis thymidylate synthase provides clues about folate bacterial metabolism. *Acta Crystallographica Section D: Biological Crystallography*, **2012**, 68, 1232-41		22
21	Structure-based selectivity optimization of piperidine-pteridine derivatives as potent Leishmania pteridine reductase inhibitors. *Journal of Medicinal Chemistry*, **2012**, 55, 8318-29	8.3	35
20	Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase. *Journal of Medicinal Chemistry*, **2011**, 54, 211-21	8.3	52
19	Identification of the binding modes of N-phenylphthalimides inhibiting bacterial thymidylate synthase through X-ray crystallography screening. *Journal of Medicinal Chemistry*, **2011**, 54, 5454-67	8.3	13
18	Correction for Cardinale et al., Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 16133-16133	11.5	78
17	Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, E542-9	11.5	66
16	Design and characterization of a mutation outside the active site of human thymidylate synthase that affects ligand binding. *Protein Engineering, Design and Selection*, **2010**, 23, 81-9	1.9	5
15	Homodimeric enzymes as drug targets. *Current Medicinal Chemistry*, **2010**, 17, 826-46	4.3	37
14	Dimer-monomer equilibrium of human thymidylate synthase monitored by fluorescence resonance energy transfer. *Protein Science*, **2010**, 19, 1023-30	6.3	15
13	Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 1448-53	11.5	106
12	Constrained dansyl derivatives reveal bacterial specificity of highly conserved thymidylate synthases. *ChemBioChem*, **2008**, 9, 779-90	3.8	4
11	Sequence-based identification of specific drug target regions in the thymidylate synthase enzyme family. *ChemMedChem*, **2008**, 3, 392-401	3.7	11
10	Synthesis of N-(5,7-diamino-3-phenyl-quinoxalin-2-yl)-3,4,5-substituted anilines and N-[4[(5,7-diamino-3-phenylquinoxalin-2-yl)amino]benzoyl]-l-glutamic acid diethyl ester: evaluation of in vitro anti-cancer and anti-folate activities. *European Journal of Medicinal Chemistry*, **2008**, 43, 189-203	6.8	11
9	Novel 3-benzoyl-2-piperazinylquinoxaline derivatives as potential antitumor agents. *Journal of Heterocyclic Chemistry*, **2006**, 43, 541-548	1.9	39

8	Antibacterial agent discovery using thymidylate synthase biolibrary screening. *Journal of Medicinal Chemistry*, **2006**, 49, 5958-68	8.3	22
7	Improving specificity vs bacterial thymidylate synthases through N-dansyl modulation of didansyltyrosine. *Journal of Medicinal Chemistry*, **2005**, 48, 913-6	8.3	16
6	The structure of Cryptococcus neoformans thymidylate synthase suggests strategies for using target dynamics for species-specific inhibition. *Acta Crystallographica Section D: Biological Crystallography*, **2005**, 61, 1320-34		9
5	Thymidylate synthase structure, function and implication in drug discovery. *Current Medicinal Chemistry*, **2005**, 12, 2241-58	4.3	79
4	Aza-boronic acids as non-beta-lactam inhibitors of AmpC-beta-lactamase. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 3979-83	2.9	12
3	A step further in the discovery of phthalein derivatives as Thymidylate Synthase inhibitors. *Arkivoc*, **2004**, 2004, 382-396	0.9	4
2	Inhibitor specificity via protein dynamics: insights from the design of antibacterial agents targeted against thymidylate synthase. *Chemistry and Biology*, **2003**, 10, 1183-93		28
1	Update on antifolate drugs targets. *Current Drug Targets*, **2001**, 2, 135-66	3	44